| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-400,424 | -368,009 | -346,397 | -349,137 | -352,861 | -160,031 | -84,532 | -73,983 | -55,570 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Share-based compensation expense | ||||||||
54,304 | 49,090 | 44,707 | 39,796 | 40,357 | 21,517 | 9,505 | 4,949 | 1,325 |
Depreciation and amortization | ||||||||
7,768 | 4,601 | 2,504 | 1,141 | 761 | 444 | 250 | 353 | 185 |
Amortization of premiums and discounts on available-for-sale securities | ||||||||
1,521 | -1,345 | -354 | -211 | -1,400 | 0 | - | -10 | -141 |
Amortization of debt issuance costs | ||||||||
2,858 | 2,178 | 1,279 | 1,242 | 1,205 | 368 | - | - | - |
Legal settlement loss | ||||||||
22,747 | - | 105,477 | 0 | 0 | - | - | - | - |
Gain on extinguishment of debt | ||||||||
18,480 | - | - | - | - | - | - | - | - |
Loss on sale of property and equipment | ||||||||
-804 | - | - | -105 | -39 | -67 | - | -1,162 | - |
Impairment of intangible asset | ||||||||
- | - | - | 104,517 | 89,557 | 3,409 | - | - | - |
Change in fair value of contingent purchase consideration | ||||||||
- | - | - | -24,661 | -27,792 | -3,301 | 1,028 | - | - |
Deferred income taxes | ||||||||
- | - | -3,218 | -31,771 | -28,874 | 761 | - | - | - |
Gain on sale of available for sale securities | ||||||||
- | - | - | - | - | - | - | - | 16 |
Non-cash acquired in-process research and development | ||||||||
- | - | - | - | - | - | - | - | 7,000 |
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | ||||||||
7,518 | 3,371 | 6,061 | 121 | 0 | 0 | - | - | - |
Inventory | ||||||||
26,160 | 49,936 | 27,508 | 0 | 0 | - | - | - | - |
Prepaid and accrued research and development expenses | ||||||||
-23,233 | -9,145 | 17,297 | 15,364 | -14,122 | -18,112 | -3,276 | -2,993 | -2,682 |
Deposit on inventory | ||||||||
- | 12,350 | 20,461 | 0 | 0 | - | - | - | - |
Other operating assets and liabilities | ||||||||
6,837 | 8,750 | 6,476 | -1,039 | 4,380 | 910 | 995 | 17 | -924 |
Accounts payable | ||||||||
12,289 | 5,770 | 5,637 | -1,544 | 8,105 | -1,369 | 958 | -758 | 1,656 |
Other accrued expenses | ||||||||
13,322 | 4,290 | 6,556 | 7,867 | 5,295 | 3,882 | -1,202 | -93 | 1,845 |
Net cash used in operating activities | ||||||||
-323,615 | -365,997 | -260,904 | -266,680 | -253,066 | -117,051 | -71,712 | -65,384 | -39,828 |
Investing activities | ||||||||
Purchases of property and equipment | ||||||||
3,290 | 9,242 | 487 | 766 | 3,035 | 2,286 | 121 | 1,058 | 446 |
Proceeds from sale of property and equipment | ||||||||
275 | - | - | 65 | 0 | 0 | - | - | - |
Deposits for sale of property and equipment | ||||||||
- | - | 2,515 | 0 | 0 | - | - | - | - |
Purchases of available-for-sale securities | ||||||||
459,835 | 500,000 | 263,500 | 0 | 392,540 | 0 | - | - | - |
Sales of available-for-sale securities | ||||||||
621,998 | 300,000 | 213,500 | 200,000 | 140,997 | 0 | - | - | - |
Maturities of available-for-sale securities | ||||||||
- | - | - | - | - | - | - | 2,000 | 9,614 |
Acquired in-process research and development - milestone payment | ||||||||
15,750 | 55,000 | 1,100 | 0 | 0 | - | - | - | - |
Acquisition of business, net of cash acquired | ||||||||
- | - | - | - | - | - | 9,913 | - | - |
Net cash provided by (used in) investing activities | ||||||||
143,398 | -264,242 | -54,102 | 199,299 | -254,578 | -2,286 | -10,034 | 942 | 9,168 |
Financing activities | ||||||||
Proceeds from the sale of common stock, net of issuance costs | ||||||||
- | 93,890 | 545,838 | 0 | 298,509 | 0 | 259,071 | 69,976 | 129,355 |
Payments on capital leases | ||||||||
1,115 | 245 | - | 0 | - | - | - | - | - |
Payment of convertible senior notes | ||||||||
169,853 | - | - | - | - | - | - | - | - |
Proceeds from the issuance of convertible senior notes, net of issuance costs | ||||||||
254,879 | 290,887 | - | 0 | - | 278,313 | - | - | 27,902 |
Proceeds from borrowings under financing agreement | ||||||||
32,871 | - | - | - | - | - | - | - | - |
Proceeds from the exercise of stock options and employee stock purchases | ||||||||
3,266 | 3,967 | 16,237 | 5,176 | 5,971 | 1,163 | 1,771 | 315 | 1,089 |
Payments on other long-term liabilities | ||||||||
160 | 35 | - | 0 | - | - | - | - | - |
Net cash provided by financing activities | ||||||||
119,888 | 388,464 | 562,075 | 5,176 | 304,480 | 279,476 | 260,842 | 70,291 | 158,346 |
Effect of exchange rate changes on cash and cash equivalents | ||||||||
286 | -547 | 943 | -365 | -757 | -690 | 35 | 12 | 42 |
Increase (decrease) in cash and cash equivalents | ||||||||
-60,043 | -242,322 | 248,012 | -62,570 | -203,921 | 159,449 | 179,131 | 5,861 | 127,728 |
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for interest | ||||||||
10,515 | 9,188 | 7,188 | 7,188 | 7,307 | 0 | - | - | - |
Non-cash investing and financing activities: | ||||||||
Acquired in-process research and development - milestone not paid as of period end | ||||||||
- | - | - | 21,100 | 0 | 0 | - | - | - |
Vesting of restricted stock units | ||||||||
5,442 | 10,808 | 12,170 | 175 | 0 | - | - | - | - |
Equipment acquired under capital lease | ||||||||
- | - | - | 0 | - | - | - | - | - |
Issuance of shares for acquisition of business | ||||||||
- | - | - | - | - | - | 173,654 | - | - |
Conversion of convertible preferred stock to common stock | ||||||||
- | - | - | - | - | - | - | - | 75,499 |
Conversion of convertible promissory notes and accrued interest to common stock | ||||||||
- | - | - | - | - | - | - | - | 35,851 |
Assets recorded for which payment (has)/has not yet occurred | ||||||||
- | - | - | - | - | - | - | - | 684 |